These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 33759353)

  • 1. Treatment allocation strategies for umbrella trials in the presence of multiple biomarkers: A comparison of methods.
    Ouma LO; Grayling MJ; Zheng H; Wason J
    Pharm Stat; 2021 Nov; 20(6):990-1001. PubMed ID: 33759353
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Bayesian adaptive design for biomarker trials with linked treatments.
    Wason JM; Abraham JE; Baird RD; Gournaris I; Vallier AL; Brenton JD; Earl HM; Mander AP
    Br J Cancer; 2015 Sep; 113(5):699-705. PubMed ID: 26263479
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Bayesian Hybrid Adaptive Randomisation Design for Clinical Trials with Survival Outcomes.
    Moatti M; Chevret S; Zohar S; Rosenberger WF
    Methods Inf Med; 2016; 55(1):4-13. PubMed ID: 26404511
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect size estimates from umbrella designs: Handling patients with a positive test result for multiple biomarkers using random or pragmatic subtrial allocation.
    Kesselmeier M; Benda N; Scherag A
    PLoS One; 2020; 15(8):e0237441. PubMed ID: 32797088
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bayesian two-stage sequential enrichment design for biomarker-guided phase II trials for anticancer therapies.
    Su L; Chen X; Zhang J; Gao J; Yan F
    Biom J; 2022 Oct; 64(7):1192-1206. PubMed ID: 35578917
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lay public's understanding of equipoise and randomisation in randomised controlled trials.
    Robinson EJ; Kerr CE; Stevens AJ; Lilford RJ; Braunholtz DA; Edwards SJ; Beck SR; Rowley MG
    Health Technol Assess; 2005 Mar; 9(8):1-192, iii-iv. PubMed ID: 15763039
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bayesian order constrained adaptive design for phase II clinical trials evaluating subgroup-specific treatment effect.
    Shan M; Guo B; Liu H; Li Q; Zang Y
    Stat Methods Med Res; 2023 May; 32(5):885-894. PubMed ID: 36919375
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimal Bayesian adaptive trials when treatment efficacy depends on biomarkers.
    Zhang Y; Trippa L; Parmigiani G
    Biometrics; 2016 Jun; 72(2):414-21. PubMed ID: 26575199
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A simulation study of outcome adaptive randomization in multi-arm clinical trials.
    Wathen JK; Thall PF
    Clin Trials; 2017 Oct; 14(5):432-440. PubMed ID: 28982263
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A subgroup cluster-based Bayesian adaptive design for precision medicine.
    Guo W; Ji Y; Catenacci DVT
    Biometrics; 2017 Jun; 73(2):367-377. PubMed ID: 27775814
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Simulation study for evaluating the performance of response-adaptive randomization.
    Du Y; Wang X; Jack Lee J
    Contemp Clin Trials; 2015 Jan; 40():15-25. PubMed ID: 25460340
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimizing a Bayesian hierarchical adaptive platform trial design for stroke patients.
    Gao G; Gajewski BJ; Wick J; Beall J; Saver JL; Meinzer C;
    Trials; 2022 Sep; 23(1):754. PubMed ID: 36068547
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Handling misclassified stratification variables in the analysis of randomised trials with continuous outcomes.
    Yelland LN; Louise J; Kahan BC; Morris TP; Lee KJ; Sullivan TR
    Stat Med; 2023 Aug; 42(19):3529-3546. PubMed ID: 37365776
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The use of Bayesian hierarchical models for adaptive randomization in biomarker-driven phase II studies.
    Barry WT; Perou CM; Marcom PK; Carey LA; Ibrahim JG
    J Biopharm Stat; 2015; 25(1):66-88. PubMed ID: 24836519
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hierarchical Bayesian clustering design of multiple biomarker subgroups (HCOMBS).
    Kang D; S Coffey C; J Smith B; Yuan Y; Shi Q; Yin J
    Stat Med; 2021 May; 40(12):2893-2921. PubMed ID: 33772843
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Bayesian response-adaptive trial in tuberculosis: The endTB trial.
    Cellamare M; Ventz S; Baudin E; Mitnick CD; Trippa L
    Clin Trials; 2017 Feb; 14(1):17-28. PubMed ID: 27559021
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical trial designs for testing biomarker-based personalized therapies.
    Lai TL; Lavori PW; Shih MC; Sikic BI
    Clin Trials; 2012 Apr; 9(2):141-54. PubMed ID: 22397801
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Bayesian prediction model between a biomarker and the clinical endpoint for dichotomous variables.
    Jiang Z; Song Y; Shou Q; Xia J; Wang W
    Trials; 2014 Dec; 15():500. PubMed ID: 25528466
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bayesian biomarker-driven outcome-adaptive randomization with an imperfect biomarker assay.
    Garcia Barrado L; Burzykowski T
    Clin Trials; 2021 Apr; 18(2):137-146. PubMed ID: 33231131
    [TBL] [Abstract][Full Text] [Related]  

  • 20. On Enrichment Strategies for Biomarker Stratified Clinical Trials.
    Wang X; Zhou J; Wang T; George SL
    J Biopharm Stat; 2018; 28(2):292-308. PubMed ID: 28933670
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.